Purple Biotech expands CAPTN-3 portfolio with IM1305

Purple Biotech (PPBT) announced its second CAPTN-3 trispecific antibody, targeting TROP2 in development. Purple Biotech has advanced development of a tri-specific antibody targeting TROP2 from its unique CAPTN-3 platform. Through activation of both the innate and adaptive immune systems, CAPTN-3 platform candidates can generate synergistic responses within the tumor microenvironment and overcome the immunosuppressive environment, which remains a major challenge in treating solid tumors. Preclinical results targeting TROP2 have demonstrated sustained tumor regression of human triple negative breast cancer in a mouse model, with no detectable tumor recurrence following treatment completion. Significant cell death induction was demonstrated in multiple tumor types, including TNBC, tongue and hypopharyngeal cancers, pancreatic and gastric cancers, at remarkably low doses.